Organic Active Ingredients TRIZ Cases

Porous cellulose particles with 1.7 to 24.0 m2/g BET surface area resolve mechanical strength versus oil absorption trade-offs.

Cyano group introduction at position 5 enhances potency and selectivity against A2a receptors.

Cyclohexyloxy-substituted heterocyclic compounds inhibit tyrosine kinase signal transduction to treat tumor diseases and benign prostatic hyperplasia.

A benzoxazole derivative with a bicyclic piperazine ring delivers potent PDE4 inhibitory activity.

Measuring Cobll1 expression levels diagnoses blast crisis transformation and tyrosine kinase inhibitor resistance, resolving BCR-ABL1 diagnostic blind spots.

A trihexyphenidyl extended release composition uses an organic acid core to enhance drug solubility.

Segmenting treatment by targeting differential miRNA expression stabilizes cardiac function and reduces fibrosis during post-infarction remodeling.

Azaindolyl compounds inhibit MEK kinase activity, addressing insufficient safety and efficacy of current cancer treatments.

Divalent metal salts form stable adducts with ticagrelor to resolve low water solubility and improve bioavailability.

A dual chamber parenteral nutrition container delivers optimized amino acid and dextrose concentrations for balanced nutrient delivery.

A flavanol-nanoparticle conjugate destabilizes tau amyloid fibrils through electrostatic disruption.

Progesterone treatment resolves benzodiazepine limitations by normalizing sleep stage distribution to reduce mid-sleep awakenings.

Antibodies targeting MUC16 truncated O-glycans overcome drug resistance in pancreatic cancer treatment.

Applying 100-400 kHz TTFields alongside sorafenib induces mitotic arrest to reduce tumor volume in hepatocellular carcinoma.

Brush-arm star polymer nanoparticles extend paclitaxel presence at vessel walls, preventing restenosis without exceeding toxic thresholds.

DLL3 antibody-PBD conjugates target tumorigenic cells while sparing normal tissue, reducing systemic toxicity and improving treatment outcomes.

RUNX1 inhibitors target transcription factors to decrease epithelial-to-mesenchymal transition severity, avoiding invasive surgery.

SGLT-2 inhibitors block glucose reabsorption to reduce proteinuria and delay renal failure progression in cats and dogs.

Heterocyclic amide compounds selectively target RIP1 kinase to resolve the contradiction between inhibition efficacy and oral bioavailability.

Thermal gelation of methacrylated cellulose hydrogels restores disc height while preventing extrusion through covalent bonding with the annulus fibrosus.

Crystalline forms of a CDK9 inhibitor improve stability and processability, resolving trade-offs between amorphous preparation ease and solid-state reliability.

A needleless injector uses igniter powder combustion to generate plasma pressure for DNA solution discharge through a nozzle unit.

Zinc oxide complex prevents menthol ester formation and crystal precipitation while maintaining skin permeability.

Modified quinone structures reduce first-pass liver metabolism while maintaining therapeutic efficacy for mitochondrial dysfunction.

An airless pump system with a metered dosage mechanism delivers precise imiquimod doses while preventing microbial contamination and formulation degradation.

Crystalline Tenapanor form A resolves hygroscopicity and stability issues by transforming the amorphous compound into a stable solid state.

Strong base addition in ibuprofen salt compositions raises aqueous pH to 9.5, eliminating oral irritation while maintaining therapeutic efficacy.

Enteric coating protects the drug from stomach acid degradation while pH-responsive materials ensure rapid intestinal absorption.

G9a inhibitors block methyltransferase activity to unsilence maternal genes, addressing silenced molecular causes of Prader-Willi syndrome.

High current density pre-treatment modifies skin permeability, enabling stable drug transport at lower energy levels.

Substituted bicyclic compounds inhibit nucleocapsid assembly, preventing drug resistance while treating chronic hepatitis B and D infections.

Novel small-molecule compounds selectively inhibit the beta-catenin/B-cell lymphoma 9 protein-protein interaction.

LNA and PMO oligonucleotides target mutant HTT hairpins to lower disease protein while preserving wild-type expression.

Ester moiety degradation via esterases bypasses cytochrome P450 metabolism, eliminating cardiac arrhythmia risks from cisapride derivatives.

Segmented compartments keep acetylsalicylic acid stable until mixing with a pre-filled organic acid salt solution, eliminating water dependency.

Feed supplementation with 25-hydroxyvitamin D3 reduces drip losses and improves meat quality without altering carcass yield.

Indirubin-3'-oxime targets the Wnt pathway to treat short stature without growth hormone side effects.

SerpinA3 polypeptides protect retinal ganglion cells, addressing optic nerve damage where pressure-lowering treatments fail.

2-Fluorodeschloroketamine treats treatment-resistant depression by flattening the dose-response curve to reduce side effects.

Aryl and heteroaryl compounds of formula I inhibit viral proliferation.

Immune regulatory oligonucleotide compounds antagonize toll-like receptor signaling, avoiding polyG secondary structures to suppress cytokine production.

Sulfur heteroaromatic ring compound inhibits poly(ADP-ribose) glycohydrolase to overcome PARP inhibitor resistance in cancer therapy.

Formula I pyrimidine compounds enhance treatment reliability by reducing side effects while suppressing viral loads in genotype 1 infections.